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associated with certain risks to the patient. In particular,
organ-transplant recipients have a higher risk of oppor-
tunistic infections2 and malignancies, such as lym-
phoma.3 Although improvements in immunosuppres-
sive therapy have significantly decreased the incidence
and morbidity of acute rejection episodes, chronic
rejection resulting in graft failure continues to limit the
long-term efficacy of allotransplantation.4,5 The induc-
tion of donor-specific immune tolerance would, in the-
ory, eliminate the need for immunosuppression and its
associated problems. It has long been a major goal of
transplant immunology research.
Although allograft rejection is a complex phenomena
involving multiple cell types and soluble factors, T lym-
phocytes play a central role in the process.6,7 The allore-
active T lymphocyte is therefore a natural target for
transplantation immunotherapy.8 Conventional treat-
C linical results of allotransplantation have improveddramatically in recent years, with 1-year graft sur-
vival of 70% to 80%.1 The need for lifelong immuno-
suppression, however, remains a major limitation and is
Background: Life-long immunosuppression is a major cause of mortality
and morbidity in transplant recipients. Gene therapy could provide new
ways to obtain tolerance and avoid indefinite immunosuppression.
EpTK mice are derived from the FVB/N strain (H2q) and express the
thymidine kinase gene of herpesvirus in all mature T cells. Thus any
mature dividing T cell can be killed in the presence of ganciclovir. We
investigated the survival of alloincompatible C57B1/6 (H2b) hearts het-
erotopically transplanted into EpTK mice given only ganciclovir from
day 0 to day 7 or 14. Methods: Abdominal cardiac transplantations were
performed in 22 control mice (untreated FVB [n = 15], ganciclovir-treat-
ed FVB [n = 5], and untreated EpTK mice [n = 2]) and in 28 EpTK mice
given ganciclovir from day 0 to day 7 (n = 15) or day 14 (n = 13).
Rejection was defined as complete cessation of cardiac beat. Histologic
examination of the grafts was performed at rejection, at day 7, or at day
100. Lymphocyte proliferation assays (concanavalin A stimulation or
mixed lymphocyte reaction) were performed at day 7 and at day 100.
Results: All control animals rejected transplants in 7 days (range, 5-9
days), whereas indefinite survival (>100 days) was observed in 89% of
the ganciclovir-treated EpTK group, irrespective of the duration of gan-
ciclovir treatment. Graft histology showed extensive cellular infiltrates
with myocyte necrosis and arteritis in the control animals but only a
mild infiltrate without necrosis or arteritis in the ganciclovir-treated
EpTK group. The proliferative responses of the tolerant mice at day 100
were identical to those of naive mice, including a preserved proliferation
against the donor’s lymphocytes in mixed lymphocyte reaction.
Conclusion: Functional transplantation tolerance of a fully incompatible
heart can be achieved without immunosuppressive drugs in this model
of suicide gene therapy. (J Thorac Cardiovasc Surg 2000;119:46-52)
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ments use mostly antibodies directed at various cell
antigens or drugs affecting the activation and multipli-
cation of B and T cells.
Another strategy would be to use the possibilities
offered by gene therapy and, more specifically, a sui-
cide-gene system. The TK suicide-gene system uses the
gene for herpes simplex virus 1 thymidine kinase.
Unlike TK from eukaryotic cells, TK of the virus can
phosphorylate nucleoside analogues such as ganci-
clovir. Monophosphated ganciclovir is then phosphory-
lated by the eukaryotic cells to triphosphate ganci-
clovir, which is incorporated into dividing cells and
stops DNA synthesis, thus leading to cell death.9
Destruction of cells is thus restricted to dividing cells
and conditioned by the presence of ganciclovir. To test
the efficacy of this system in the therapy of T-cell medi-
ated diseases, we generated a strain of mice, the trans-
genic mouse line EpTK, in which a TK transgene is
only expressed in T lymphocytes.10,11 The regulating
sequences come from the human CD4 gene, the pro-
moter of which is remarkably similar in sequence to
murine promoters, and from the murine CD4 gene
enhancer.12
This system destroys T lymphocytes in a selective
(replicating cells) and conditional (in the presence of
ganciclovir) way.
Methods
Animals. All mice were aged 6 to 15 weeks and weighed
15 to 30 g. Donor mice were male C57B1/6 animals of the H-
2b haplotype (CERJ laboratory, Le Genest-Saint-Isle,
France). Recipient mice were either FVB mice of the H-2q
haplotype (IFFA Credo laboratory, Domaine des Oncins,
L’Arbesle, France) or transgenic EpTK mice (derived from
the FVB strain and raised in the facility of the Pitie-
Salpetriere Hospital, Paris, France). Third-party mice were
BALB/c of the H-2d haplotype (CERJ laboratory). All ani-
mals received humane care in compliance with the guide for
the care and use of laboratory animals.
Murine heterotopic heart transplantation. Intra-abdom-
inal heterotopic cardiac transplantation was performed by
using techniques similar to those described by Corry and
colleagues.13 The donor mouse was anesthetized with 100
mg/kg intraperitoneal pentobarbital (Sanofi). The mouse was
prepped with 90% alcohol, and a full midline laparotomy
was performed under full sterile conditions. After adminis-
tering 250 IU of heparin into the inferior vena cava, the inci-
sion was extended into a median sternotomy. Under 10×
magnification, the inferior vena cava was ligated with a 9/0
monofilament (Premio, Peters) suture and divided distally.
Under 20× magnification, the aorta and pulmonary artery
were separated and divided as far distally as possible. The
superior vena cava and pulmonary veins were then ligated en
masse with a 6-0 silk suture. The heart was removed and
stored in cold Ringer’s lactate solution (0°C-4°C) with
antibiotics (250,000 IU penicillin plus 100 mg gentamicin in
500 mL of solution).
The recipient mouse was anesthetized with 50 mg/kg
intraperitoneal pentobarbital and 2.5 µg of intraperitoneal
atropine sulfate. Cefazolin, 25 mg/kg administered intramus-
cularly, was administered for antibiotic prophylaxis. Under
identical sterile conditions, a full midline laparotomy was
performed, and the intestines were retracted with an antibiot-
ic-soaked sponge. Under 20× magnification, the infrarenal
aorta and inferior vena cava were dissected over a length of 5
mm. Lumbar branches were ligated by using 9-0 polyvinyl-
idene difluoride monofilament (Premio, Peters). The aorta
and vena cava were then encircled proximally and distally by
using 6-0 silk ligatures and occluded by using a “meunier”
knot. Under 40× magnification, a longitudinal venotomy and
aortotomy were performed with a 26-gauge needle.
After the donor heart was removed from storage, the donor
aorta and pulmonary artery were anastomosed to the recipi-
ent aorta and vena cava, respectively, by using a continuous
running 10-0 Ethicon suture (Ethicon, Inc, Somerville, NJ).
The anastomoses took about 20 minutes to complete, and the
ischemic heart was protected by dripping cold lactated
Ringer’s solution on it at frequent intervals. The distal
occluding ties were removed from the recipient’s aorta and
vena cava, followed by the proximal ties. After a brief period
of ventricular fibrillation, the heart usually reverted sponta-
neously to normal sinus rhythm. After carefully replacing the
Table I. Results of heart survival
Group Recipients Treatment Survival (d) MST (d)
A FVB/N (10) None 6 (×3), 7 (×6), 9 7
B1 Littermates (5) Ganciclovir-7 days 6, 7 (×4) 7
B2 Littermates (5) None 5, 6, 7 (×3) 7
C1 EpTK (4)* Ganciclovir-7 days 26, >100 (×3) >100
C1 EpTK (10)* Ganciclovir-14 days 15, 37, >100 (×8) >100
C2 EpTK (2) None 7 (×2) 7
All donors were from C57B1/6 origin.
MST, Mean survival time.
*The 4 mice put to death at day 7 and the 10 dead are not reported.
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intestines in the abdomen and instilling 0.5 mL of lactated
Ringer’s solution with antibiotics, the abdominal wall was
closed with 2 running sutures. Graft function was monitored
daily by 2 separate investigators with direct palpation, and
rejection was suspected when a sharp decline in the intensity
of the cardiac impulse was noted. Rejection never led to death
of the recipient animal.
Ganciclovir administration. Ganciclovir (Cymevan,
Roche) was administered by continuous subcutaneous infu-
sion initiated immediately postoperatively, with a miniosmot-
ic pump Alzet (Alza Corp, Palo Alto, Calif) at a rate of 1 µL/h
(50 mg/kg per day). The treatment was continued for 7 days
(model 2001) or 14 days (model 2002).
Histology. All hearts were excised from the recipients and
subjected to microscopic examination. Five-micrometer paraf-
fin sections of ventricular tissue were stained with hema-
toxylin-eosin-safran stain and examined histologically. The
samples were graded for cellular infiltrate, necrosis, and arteri-
tis by 2 separate, blinded investigators on a scale of 0 to 3+.
Mixed lymphocyte culture and concanavalin A stimula-
tion. The assay medium was RPMI-1640 medium (Bio
Whittaker, Fontenay-sous-bois, France) supplemented with 2
mmol/L L-glutamine, 1% penicillin-streptomycin-neomycin,
50 µmol/L β2-mercaptoethanol (Life Technologies-Gibco
BRL, Cergy-Pontoise, France), and 10% fetal calf serum
(Dominique Dutscher SA, Brumath, France).
Cells used in these experiments were splenocytes from the
different mice strains. Splenocytes were gently passed
through a 70-µm cell strainer (Falcon; Becton Dickinson, Le
Pont de Claix, France), and erythrocytes were lysed by treat-
ment with an ammonium chloride and potassium solution.
A total of 100,000 responder cells were stimulated in trip-
licate in round-bottomed, 96-well microplates in 0.2 mL of
assay medium with 3 µg/mL concanavalin A (Sigma-Aldrich,
Saint-Quentin-Fallavier, France).
For the mixed lymphocyte culture, responder cells at the
same concentration were stimulated by the addition of
200,000 splenocytes treated with mitomycin C (Sigma-
Aldrich, Saint-Quentin-Fallavier, France).
Cells were cultured in a 5% CO2 incubator at 37°C.
Proliferation was assessed by incorporation of 1 µCi of
3H-thymidine (ICN Pharmaceuticals, Orsay, France) per well
after 2 days of culture for the mitogen stimulation or after 4
days for the mixed lymphocyte culture. Cells were pulsed for
18 to 24 hours before harvesting. Radioactivity was counted
by using the Tomtec 96-well harvester and the 1450 micro-
beta Plus-liquid scintillation counter, and the results were
recorded as mean counts per minute.
Statistical analysis. Data are presented as means ± SEM.
Statistical significance was assessed by using analysis of
variance and the Student unpaired t test or Kaplan-Meier sur-
vival curves.
Results
Graft survival. We performed 50 abdominal hetero-
topic cardiac transplantations with C57B1/6 mice as
donors (Table I).
Group A, B1, and B2 recipients were nontransgenic
FVB mice. Group C recipients were transgenic mice
treated by ganciclovir (C1) or untreated (C2).
Ten mice died in group C1 (on day 2, 6, 11, 18, 27,
32, 35, 50, 52, and 62) with no evident cause of death
at systematic autopsy, including no evidence of sepsis
or neoplasia, and with a strongly beating heart the day
before. Four mice were killed at day 7 for histology.
Treatment with ganciclovir 7 or 14 days after trans-
plantation in EpTK mice significantly prolonged allo-
graft survival to greater than 100 days in 11 of 14 ani-
mals. In contrast, control animals consistently rejected
their grafts between days 6 and 9 (P < .0001).
Three rejections were observed in the C1 group
(EpTK mice treated with ganciclovir). No difference
was found between the groups treated for 7 or 14 days
with ganciclovir (P = .39; Table I).
Macroscopic appearance. Rejecting cardiac allo-
grafts had a characteristic macroscopic appearance.
They were dilated, mottled with dark coloration, and
exhibited no visible beating. In contrast, nonrejecting
grafts were small with normal coloration and exhibited
strong and visible contractions.
Histology. The histologic appearance of allografts
from the ganciclovir-treated EpTK group was com-
pared with that of allografts from the control groups.
Histologic evaluation was done between 6 and 8 days
after transplantation (4 EpTK mice were killed at
day 7). Histology of the hearts from acutely rejecting
Fig 1. Histologic results. Comparison between ganciclovir-
treated EpTK mice and control mice. Results are given in
means of score for each data.
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animals (control animals) demonstrated a marked
cellular graft infiltrate with destruction of myocyte
architecture.
Heart transplants from ganciclovir-treated EpTK
mice also had a marked cellular infiltrate but with pre-
served myocyte architecture. The average rejection
grade in the ganciclovir-treated EpTK group was
between 1A and 1B; the control group, on the other
hand, demonstrated significant necrosis and arteritis
with grade 4 rejection in all animals.
Fig 1 shows the histologic aspect of allograft at day 7
after transplantation for each group.
Fig 2. Mixed lymphocyte reaction of splenocytes after stimulation with donor and third-party antigens.
Fig 3. In vitro responsiveness of splenocytes stimulated by a nonspecific stimulant (mitogen) concanavalin A.
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Of the 7 mice who had standard histology between
day 27 and day 101, 5 showed no necrosis at all, and 2
showed very mild necrosis. Six showed no arteritis,
whereas 1 mouse killed at day 100 had some arteritis.
The cellular infiltrate was present in most recipients,
but it does not appear to destroy cardiac architecture.
Mixed lymphocyte culture and concanavalin A
stimulation. The mixed lymphocyte reaction of cells
from treated mice and control mice (naive FVB/N mice
and treated transplanted nontransgenic litter mates)
after stimulation with donor and third-party antigens
were evaluated. Results are shown in Fig 2.
The proliferative response in ganciclovir-treated
EpTK mice killed at day 7 was partially inhibited
when stimulated by donor cells in comparison with
third-party cells, but by day 100 after transplantation,
these mice responded normally to donor and third-
party antigens.
We also studied in vitro responsiveness of spleno-
cytes from the same mice groups stimulated by con-
canavalin A (Fig 3).
Splenocytes from ganciclovir-treated EpTK mice
killed at days 7 or 100 exhibited a strong proliferative
response to mitogen.
Lymphocyte count. Blood cell count realized at the
seventh day after transplantation on 6 ganciclovir-treat-
ed EpTK mice revealed a normal lymphocyte count
(average of 3300/mm3 [± 1230] compared with levels
in control mice of 3480/mm3 [± 520]).
Discussion
The suicide-gene system used in this study attempts
to induce donor-specific tolerance by targeting repli-
cating T lymphocytes for self-destruction during the
first days after transplantation. By genetically modify-
ing the recipient’s T lymphocytes, we have acquired the
ability to selectively destroy replicating T lymphocytes
during ganciclovir administration. The assumption is
that during this early postoperative period, most repli-
cating T lymphocytes will be alloreactive and, con-
versely, that most alloreactive T lymphocytes will be
replicating (and therefore suicidal). We hypothesized
that we could successfully eliminate the pool of allore-
active T lymphocytes during this period and conse-
quently induce long-term specific tolerance to the allo-
graft. Indeed, Cohen and colleagues11 used that same
strain of mice in a bone-marrow transplant model. The
investigators subjected nontransgenic mice to lethal
irradiation and reconstituted the mice with allogeneic T
cell–deplated bone marrow and allogeneic T cells from
transgenic mice. Subsequent treatment with a 7-day
course of ganciclovir prevented graft-versus-host dis-
ease (GVHD). The pool of alloreactive mature lym-
phocytes that were reactive to the host (ie, those caus-
ing GVHD) was apparently successfully destroyed by
the ganciclovir treatment, rendering the grafted allo-
geneic hematopoietic cells incapable of causing
GVHD. The specific nature of this protection was con-
firmed by the fact that donor T lymphocytes were iden-
tified in the recipient that reacted normally to third-
party cells. These lymphocytes, of course, were
specifically tolerant of the recipient.
Our results, using a vascularized graft model, demon-
strate a dramatic increase in cardiac allograft survival
in the ganciclovir-treated transgenic mice. Because
ganciclovir-treated nontransgenic mice (group B1), as
well as untreated transgenic mice (group C2), rejected
their grafts, as did the untreated controls, we can rule
out an immunosuppressive effect of the ganciclovir
itself or an intrinsic immunodeficiency of the trans-
genic mice.
There was little histologic evidence of myocardial
injury in ganciclovir-treated transgenic mice when
compared with 4 different control groups. At approxi-
mately 1 week, the histologic pattern is quite clear,
with significant cellular infiltration, necrosis, and
arteritis in all control groups. In contrast, the ganci-
clovir-treated transgenic mice showed only mild cellu-
lar infiltration without evidence of necrosis or arteritis.
All control mice rejected their allografts within 9 days.
Although 3 ganciclovir-treated transgenic mice reject-
ed their grafts between 15 and 37 days (rejection relat-
ed to inadequate delivery of ganciclovir), the remaining
11 continued to function until they were killed at more
than 100 days. Although a mild cellular infiltrate per-
sisted in these long-term survivors, necrosis and arteri-
tis remained rare and, when present, quite mild. The
significance of this persistent mild cellular infiltrate,
without evidence of myocardial injury or graft dys-
function, is not clear from our study. However, it is a
common finding in other models of allograft toler-
ance14,15 and may, in fact, consist of suppressive T lym-
phocytes that protect the allograft from rejection.16,17
Tolerance in this model is achieved without any long-
lasting immunodepletion, as shown by a normal lym-
phocyte count and normal proliferative responses in the
tolerant mice. Both 7 and 14 days of ganciclovir treat-
ment seemed to confer equal graft protection in the
transgenic mice, suggesting that early events affecting
the alloreactive lymphocytes have a long-lasting effect.
Because tolerant mice have, at day 100, a normal pro-
liferative response against the donor cells, a simple,
time-limited, clonal deletion of alloreactive T lympho-
cytes cannot by itself explain the long-lasting tolerance
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seen. Future work identifying the immune mechanisms
at play is clearly warranted.
This system could be used in patients through ex vivo
transfection of bone marrow cells and subsequent
autologous bone marrow transplantation at the time of
solid organ transplantation.
In summary, we have induced a long-lasting func-
tional tolerance in a murine model of vascularized car-
diac allotransplantation without the use of any
immunosuppressive agent. Although many hurdles will
have to be overcome before this system could be
applied to clinical transplantation, these promising
early results appear to validate the principles on which
the suicide-gene system is based.
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Discussion
Dr Verdi J. DiSesa (Chicago, Ill). You gave the ganci-
clovir for 7 days, is that what I saw on your slide?
Dr Braunberger. We gave ganciclovir for 7 days in 15
mice and for 14 days in 13 mice, with exactly the same sur-
vival rate.
Dr DiSesa. When did you start it relative to the transplant? 
Dr Braunberger. We start immediately postoperatively,
just before the mouse wakes up.
Dr DiSesa. Would you not hypothesize, though, that any
stimulus that would lead to T-cell proliferation would be
inhibited by this therapy? 
Dr Braunberger. That is correct.
Dr DiSesa. So if the mouse was exposed to some infec-
tious agent that ordinarily would cause his T-cell response to
mount, that would be blunted as well.
Dr Braunberger. It appears that a treatment of 7 days is
enough to induce tolerance, and we hope that in this 7-day
period, the T-cell proliferation will be essentially alloreactive
T cells. If infectious T cells are destroyed, we hope that it will
be a limited phenomenon.
Dr DiSesa. So you think that that period of vulnerability
would be confined to the period during which you are giving
the ganciclovir?
Dr Braunberger. Yes, that is the fundamental principle of
this model. If there is no ganciclovir, proliferative T cells are
not destroyed.
Dr DiSesa. The problem in thinking how to apply this clin-
ically is that making human transgenic recipients is probably
going to be somewhat difficult. 
Dr Braunberger. It may be possible to do bone marrow
autotransplantation with a step of ex vivo transfection. This
would be followed by organ transplantation, a short course of
ganciclovir, and any other immunosuppressive treatment. Of
course, we will need more data, and a primate experimental
model will give valuable information before trying the treat-
ment on human beings. This new strategy could be particu-
larly interesting in transplantation of organs with a very high
rate of rejection, like intestines or lungs.
Dr James L. Cox (Washington, DC). What happens after a
hundred days? 
Dr Braunberger. We killed most mice in this study, but we
allowed a few to live more than 200 days with a beating heart.
Because this strain of mice usually dies after 1 year, we were
obliged to sacrifice them after that period.
Dr Cox. Do you ever re-administer ganciclovir?
Dr Braunberger. Never. We use a unique 7-day treatment.
Dr Cox. Would there be any advantage to re-administering
it at 200 days or so? 
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Dr Braunberger. Probably. Our goal was to demonstrate
that it was possible to achieve tolerance only with a very short
treatment. Of course, in human beings, it might be possible
to treat rejection episodes with repeated short courses of
ganciclovir.
Dr Paul Kurlansky (Miami Beach, Fla). I am just trying
to understand what is going on in this magnificent work.
Could you please explain what exactly is happening in terms
of the DNA? Does the DNA message get incorporated per-
manently into the T cells and does it also get incorporated
elsewhere in the genetic information, or is it incorporated in
such a way that the T-cell mechanism uses this DNA, but it is
not a permanent resident in the actual DNA structure of the cell? 
Dr Braunberger. The gene is permanently incorporated
into the genome. Because gene expression is controlled by
CD4 promoter, it is expressed only in mature T cells.
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